Subcutaneous application of gammanorm®

Completed

• Conditions: Primary immunodeficiency syndromes/severe secondary hypogammaglobulinaemia; Haematological Disorders

• Registration Number: ISRCTN66955626
• Lead Sponsor: Octapharma GmbH (Germany)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2014-09-23
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Patients of any gender and age, who receive treatment with gammanorm®

Exclusion Criteria

Hypersensitivity to any of the components

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Information about the treatment with gammanorm® in home therapy and the health-related quality of life will collected by using CRFs and appropriate questionnaires (SF-36 and CHQ-PF50).

Secondary Outcome Measures

Name	Time	Method
Efficacy of treatment will be measured by evaluating laboratory data, if available.